Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2013

View Archived Issues

Mayo Clinic licenses patient-derived xenograft models of cancer to WuXi PharmaTech

Tricyclo-DNA oligonucleotides show promise for SMA and DMD

Swedish Orphan Biovitrum provides update on pipeline candidates

Daiichi Sankyo updates pipeline progress of second quarter of fiscal 2013

Biomarker predicts exacerbations in cystic fibrosis patients

AB Pharma and Zannan SciTech identify novel HCV NS5A inhibitors

First patient enrolled in Serodus' phase IIa trial of SER-100

Phase II trial of Zerenex in NDD-CKD meets all primary and key secondary endpoints

IDMC recommends continuation of Cel-Sci's pivotal trial of Multikine

Omeros reports data for OMS-721 from model of age-related macular degeneration

AEterna Zentaris submits NDA to FDA for macimorelin acetate

Five Prime Therapeutics licenses proprietary antibodies to ADC Therapeutics

Trophos completes pivotal phase II/III study of olesoxime in spinal muscular atrophy in Europe

Inducers of immune tolerance increased in cystic fibrosis airway neutrophils

Ajinomoto reports phase IIa results for AJM-300 in ulcerative colitis

Takeda reviews highlights of second quarter of fiscal 2013

GE Healthcare tests novel PET tracers for evaluating traumatic brain injury

Novogen and Yale University create joint venture to develop drugs for ovarian cancer

Prima Biomed grants CVac license to Neopharm for Israel

Researchers in the U.S. and Taiwan present new ganciclovir prodrugs

Cancer Research Technology reports novel CDK9 inhibitors for cancer

U.S. team synthesizes new anticancer agents

Novel arginase inhibitors synthesized by Mars

Biota Scientific Management discloses new NS5B inhibitors for HCV infection

Novo Nordisk presents pipeline developments of third quarter 2013

New phase II study investigates ADI-PEG-20 for relapsed or refractory AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...